Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Peter G. M. Mol"'
Autor:
Patricia McGettigan, Sieta T. de Vries, Carla J. Jonker, Peter G. M. Mol, Arno W. Hoes, H. Marijke van den Berg
Publikováno v:
Drug Safety. ADIS INT LTD
Drug Safety
Drug Safety
Introduction In rare diseases, registry-based studies can be used to provide natural history data pre-approval and complement drug efficacy and/or safety knowledge post-approval. Objective The objective of this study was to investigate the opinion of
Autor:
Peter G. M. Mol, Christina E. Hoeve, Esther de Vries, Sabine M. J. M. Straus, Miriam C. J. M. Sturkenboom
Publikováno v:
Drug Safety, 44, 73-82. ADIS INT LTD
Drug Safety, 44(1), 73-82. Adis
Drug Safety
Drug Safety, 44(1), 73-82. Adis
Drug Safety
Introduction When serious medication errors (ME) are identified, communication to the field may be necessary. In the EU, communication of serious safety issues, such as medication errors associated with adverse drug reactions, is done through direct
Autor:
H. Marijke van den Berg, Peter G. M. Mol, Arno W. Hoes, Carla J. Jonker, Katrien Oude Rengerink
Publikováno v:
Haemophilia
Haemophilia, 26(5), 809-816. Wiley
Haemophilia, 26(5), 809-816. Wiley
Aim The aim of this study was to investigate whether a disease registry could serve as a suitable alternative to clinical studies to investigate safety of orphan drugs in children. Methods We used individual patient data from previously untreated pat
Autor:
Peter G. M. Mol, Sieta T. de Vries, Taco B. M. Monster, Esther de Vries, Jacqueline G. Hugtenburg, Petra Denig
Publikováno v:
Drug Safety, 43(7), 677-690. Adis International Ltd
Drug Safety
de Vries, E, Denig, P, de Vries, S T, Monster, T B M, Hugtenburg, J G & Mol, P G M 2020, ' Drug Safety Issues Covered by Lay Media : A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands ', Drug Safety, vol. 43, no. 7, pp. 677-690 . https://doi.org/10.1007/s40264-020-00922-7
Drug Safety, 43(7), 677-690. ADIS INT LTD
Drug Safety
de Vries, E, Denig, P, de Vries, S T, Monster, T B M, Hugtenburg, J G & Mol, P G M 2020, ' Drug Safety Issues Covered by Lay Media : A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands ', Drug Safety, vol. 43, no. 7, pp. 677-690 . https://doi.org/10.1007/s40264-020-00922-7
Drug Safety, 43(7), 677-690. ADIS INT LTD
Background Some drug safety issues communicated through direct healthcare professional communications (DHPCs) receive substantial media coverage, while others do not. Objectives The objective of this study was to assess the extent of coverage of drug
Publikováno v:
Pharmacoepidemiology and Drug Safety
Pharmacoepidemiology and Drug Safety, 28(9), 1175-1179. Wiley
Pharmacoepidemiology and Drug Safety, 28(9), 1175-1179. Wiley
PURPOSE: Little is known about adverse drug events (ADEs) experienced over time during chronic drug use. The purpose of this study was to assess ADE patterns experienced by patients with diabetes.METHODS: Patients who received an oral glucose-lowerin
Autor:
Jeroen V. Koomen, Jasper Stevens, Margje H. Monster-Simons, Hiddo J. L. Heerspink, Peter G. M. Mol
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
Aims: Cardiovascular outcome trials with anti-diabetic drugs suggest that additional cardiovascular benefit can be achieved independent of improving glycaemic control. Nonetheless, dose selection of anti-diabetic drugs is typically based solely on gl
Autor:
Marieke J. H. J. Dekker, Sieta T. de Vries, Carolien H. M. Versantvoort, Ellen G. E. Drost-van Velze, Mansi Bhatt, Peter J. K. van Meer, Ineke K. Havinga, Christine C. Gispen-de Wied, Peter G. M. Mol
Publikováno v:
Frontiers in Medicine, 8:643028. Frontiers Media S.A.
Frontiers in Medicine, Vol 8 (2021)
Frontiers in Medicine
Frontiers in Medicine, Vol 8 (2021)
Frontiers in Medicine
This study assessed to what extent women were included in all phases of drug development; whether the clinical studies in the marketing authorization application dossiers include information per sex; and explored whether there are differences between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e99372f2cc694c0852e421b6b6bdbb6
https://research.rug.nl/en/publications/217368d8-d3c9-4f97-a347-0bc4f4398f93
https://research.rug.nl/en/publications/217368d8-d3c9-4f97-a347-0bc4f4398f93
Autor:
Ilaria Baldelli, Anna Marie Coleman, Ivana Šipić, Petra Denig, Sieta T. de Vries, Peter G. M. Mol, Adriana Andrić, Amelia Cupelli, Line Michan, Miguel-Ángel Maciá Martínez, Maartje J. M. van der Sar, Yvette Escudero, Alfonso Rodríguez Pascual
Publikováno v:
Drug Saf
National competent authorities (NCAs) use Direct Healthcare Professional Communications (DHPCs) to communicate new drug safety issues to healthcare professionals (HCPs). More knowledge is needed about the effectiveness of DHPCs and the extent to whic
Autor:
Petra Denig, Corine Ekhart, E P van Puijenbroek, Nanne Kleefstra, Jako S. Burgers, S T de Vries, Peter G. M. Mol
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 85(7), 1507-1515. Wiley
British Journal of Clinical Pharmacology, 85(7), 1507-1515. Wiley
AimsWe aimed to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use.MethodsADRs spontaneously reported by healthcare p
Publikováno v:
British Journal of Clinical Pharmacology. 84:2729-2746
Aims Understanding how much healthcare professionals (HCPs) know about medication can help in devising strategies to improve rational medication use. This study aimed to synthesize information on the level of medication knowledge of HCPs in Africa. M